CMND — Clearmind Medicine Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1892500 ·
Last close
$1.68
Market Cap
$2.50M
52W High
$4.66
52W Low
$1.43
ADV30
187,111
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Apr 2026 | 0 | — | -1,571,209 | -2,047,653 | 14,523,512 | 11,415,719 | 3,032,771 |
| Jan 2026 | 0 | — | -3,659,915 | -3,854,583 | 11,143,419 | 9,257,766 | 2,905,011 |
| Oct 2025 | 0 | — | -1,456,258 | -687,842 | 6,083,052 | 3,923,058 | 4,890,456 |
| Jul 2025 | 0 | — | -1,407,764 | -1,313,592 | 3,969,546 | 3,495,338 | 2,903,878 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-6,223,694
Investing CF
$-1,061,480
Financing CF
$14,223,192
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-202.25
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-33,781,960
Inventory
—
Receivables
$551,693
ST Investments
$2,177,460
EBIT TTM
$-7,874,653
Pretax Income TTM
$-7,885,947
Interest Exp TTM
$11,294
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Oct 2025 | 0 | -5,667,177 | -3,856,983 | 6,083,052 | 4,890,456 | — | -4,734,498 |
| Oct 2024 | 0 | -5,744,925 | -5,254,678 | 7,255,414 | 4,147,862 | — | -4,858,659 |
| Oct 2023 | 0 | -6,303,434 | -8,620,837 | 5,953,288 | 4,969,816 | — | -6,301,472 |
| Oct 2022 | 0 | -6,251,431 | -6,894,868 | 826,415 | 1,932,413 | — | -3,724,494 |
| Oct 2021 | — | — | — | — | — | — | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LIFD | LFTD PARTNERS INC. | $2.52M | $0.17 | — |
| PPBT | PURPLE BIOTECH LTD. | $2.54M | $1.56 | — |
| BIXT | BIOXYTRAN, INC | $2.44M | $0.02 | — |
| ACUT | Accustem Sciences Inc. | $2.57M | $0.16 | — |
| NXTS | Nexentis Technologies Inc. | $2.59M | $1.78 | — |
News headlines (Yahoo Finance, 1h cache)
Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
2026-08-24 12:03 · Yahoo
Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint
2026-08-13 11:36 · Yahoo
Clearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study
2026-08-06 12:00 · Yahoo
Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company
2026-08-03 12:02 · Yahoo
Clearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part A of its FDA-Regulated Clinical Trial
2026-07-30 12:30 · Yahoo
Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics Market
2026-07-20 11:55 · Yahoo
Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction
2026-07-17 11:32 · Yahoo
Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI
2026-07-16 13:30 · Yahoo
Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial
2026-07-13 12:17 · Yahoo
Clearmind Medicine Responds to the U.S. Administration’s RFI for Addiction Treatment Innovations as Part of the Great American Recovery Initiative
2026-07-10 12:32 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.